Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in Restless Legs Syndrome Patients With Iron-deficiency Anemia

Trial Profile

Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in Restless Legs Syndrome Patients With Iron-deficiency Anemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Jul 2017

At a glance

  • Drugs Ferric carboxymaltose (Primary)
  • Indications Restless legs syndrome
  • Focus Therapeutic Use
  • Sponsors Luitpold Pharmaceuticals
  • Most Recent Events

    • 24 May 2017 Status changed from not yet recruiting to recruiting.
    • 09 May 2017 Planned End Date changed from 1 Jul 2018 to 1 Mar 2020.
    • 09 May 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top